The Experts below are selected from a list of 9447 Experts worldwide ranked by ideXlab platform
Udho Thadani - One of the best experts on this subject based on the ideXlab platform.
-
Severe symptomatic Sinus Bradycardia associated with mesalamine use
The American journal of gastroenterology, 1998Co-Authors: Sam Asirvatham, Cherian Sebastian, Udho ThadaniAbstract:A 29-yr-old white woman was hospitalized with bloody diarrhea secondary to ulcerative colitis. Within 24 h of receiving intravenous steroids, loperamide, and mesalamine, she developed symptomatic hypotension, severe Sinus Bradycardia, Sinus pauses, and junctional escape beats. The hypotension and Sinus Bradycardia resolved after discontinuing mesalamine. She had a family history of conduction tissue disease but her exercise ECG and Holter studies were normal. She was rehospitalized 6 wk later with an exacerbation of ulcerative colitis and, within 8 h of receiving mesalamine, developed hypotension and severe Sinus Bradycardia, which resolved after stopping mesalamine. Thus mesalamine should be used with caution, especially in patients predisposed to cardiac conduction tissue disease.
Xu Zhi Yun - One of the best experts on this subject based on the ideXlab platform.
-
THE FOLLOW-UP OBSERVATION FOR VVI AND DDD PACING IN Sinus Bradycardia AFTER VALVE REPLACEMENT
Heart, 2012Co-Authors: Chen Min, Xu Zhi YunAbstract:Objectives To compare the clinical effects of VVI and DDD pacing in Sinus Bradycardia in patients after valve replacement. Methods All 29 patients with Sinus Bradycardia after valve replacement were divided into two groups by different pacing-mode. DDD group (n=17), VVI group (n=12). Mean follow-up was 28 months; Follow up the changes of left ventricular ejection fraction, fractional shortening and the size of atrial ventricular. The occurrence of permanence atrial fibrillation, the hospitalisation for heart failure, the stroke and the death. Results All patients had no complications in Pacemaker implantation. There was none of stroke and death during the follow-up period. The incidence rate of permanence AF in DDD group was significantly lower than its in DDD group; The hospitalisation rate for heart failure in DDD group was significantly lower than its in VVI group .The left atrial volume and diameter VVI group was significantly increased compared with baseline, which were no significantly increased in DDD group;. The ejection fraction in VVI group was lower than that in DDD group (p Conclusions DDD pacing-maker in the patient, who with Sinus Bradycardia after valve replacement, get the lower ratio of permanence atrial fibrillation, the lower ratio of the hospitalisation for heart failures and improve the cardiac structure and function.
Michael Hofbeck - One of the best experts on this subject based on the ideXlab platform.
-
Fetal Sinus Bradycardia and the long QT syndrome.
American journal of obstetrics and gynecology, 2001Co-Authors: Ernst Beinder, Tomas Grancay, Theresa Menéndez, Helmut Singer, Michael HofbeckAbstract:Abstract Objective: Recent evidence in literature shows that the long QT syndrome accounts for a fraction of the sudden infant death syndrome. Newborn infants with prolongation of the Q-T interval often show Sinus Bradycardia, which led us to test whether children who were diagnosed with long QT syndrome also show Sinus Bradycardia in the cardiotocogram before birth. Study Design: We identified 18 children who were born from singleton pregnancies at or near term in whom long QT syndrome (corrected QT interval, >0.440 second) was diagnosed after birth or in childhood. Cardiograms during pregnancy and delivery were available from 17 of the 18 children. Results: The cardiotocogram showed persistent fetal Sinus Bradycardia (baseline heart rate permanently below 120 beats/min) in 12 of 17 fetuses (71%) with long QT syndrome. Two fetuses had additional intermittent tachyarrhythmias. Conclusion: Sinus Bradycardia in the cardiotocogram during delivery or in pregnancy may indicate long QT syndrome in the fetus. Postnatal electrocardiography should be performed in these children to rule out or confirm a prolongation of the Q-T interval. (Am J Obstet Gynecol 2001;185: 743-7.)
Sam Asirvatham - One of the best experts on this subject based on the ideXlab platform.
-
Severe symptomatic Sinus Bradycardia associated with mesalamine use
The American journal of gastroenterology, 1998Co-Authors: Sam Asirvatham, Cherian Sebastian, Udho ThadaniAbstract:A 29-yr-old white woman was hospitalized with bloody diarrhea secondary to ulcerative colitis. Within 24 h of receiving intravenous steroids, loperamide, and mesalamine, she developed symptomatic hypotension, severe Sinus Bradycardia, Sinus pauses, and junctional escape beats. The hypotension and Sinus Bradycardia resolved after discontinuing mesalamine. She had a family history of conduction tissue disease but her exercise ECG and Holter studies were normal. She was rehospitalized 6 wk later with an exacerbation of ulcerative colitis and, within 8 h of receiving mesalamine, developed hypotension and severe Sinus Bradycardia, which resolved after stopping mesalamine. Thus mesalamine should be used with caution, especially in patients predisposed to cardiac conduction tissue disease.
Mandeep S. Sidhu - One of the best experts on this subject based on the ideXlab platform.
-
Resolution of Sinus Bradycardia, high‐grade heart block, and left ventricular systolic dysfunction with rituximab therapy in Henoch‐Schonlein purpura
Internal medicine journal, 2018Co-Authors: Mikhail Torosoff, Thomas Breen, Sujata Balulad, Santosh K. Padala, Radmila Lyubarova, Henry Tan, Mandeep S. SidhuAbstract:Henoch-Schonlein purpura (HSP) is a rare, typically self-limited, multi-organ vasculitis. Cardiac involvement with HSP carries high morbidity and mortality, thus requiring early aggressive immunosuppressive therapy. We report a case of HSP complicated with acute systolic left ventricular (LV) dysfunction, symptomatic Sinus Bradycardia and high-grade atrio-ventricular (AV) heart block. Cyclophosphamide, a commonly used agent in HSP, was contraindicated due to the patient's presentation with acute renal failure. Treatment with monoclonal antibody rituximab and corticosteroids was initiated with an improvement in and resolution of LV systolic dysfunction, Sinus Bradycardia and AV block. We believe this is the first published report on rituximab treatment in HSP with cardiac involvement manifesting with severe LV systolic dysfunction, Sinus Bradycardia and high-grade AV block.
-
resolution of Sinus Bradycardia high grade heart block and left ventricular systolic dysfunction with rituximab therapy in henoch schonlein purpura
Internal Medicine Journal, 2018Co-Authors: Mikhail Torosoff, Thomas Breen, Sujata Balulad, Santosh K. Padala, Radmila Lyubarova, Henry Tan, Mandeep S. SidhuAbstract:Henoch-Schonlein purpura (HSP) is a rare, typically self-limited, multi-organ vasculitis. Cardiac involvement with HSP carries high morbidity and mortality, thus requiring early aggressive immunosuppressive therapy. We report a case of HSP complicated with acute systolic left ventricular (LV) dysfunction, symptomatic Sinus Bradycardia and high-grade atrio-ventricular (AV) heart block. Cyclophosphamide, a commonly used agent in HSP, was contraindicated due to the patient's presentation with acute renal failure. Treatment with monoclonal antibody rituximab and corticosteroids was initiated with an improvement in and resolution of LV systolic dysfunction, Sinus Bradycardia and AV block. We believe this is the first published report on rituximab treatment in HSP with cardiac involvement manifesting with severe LV systolic dysfunction, Sinus Bradycardia and high-grade AV block.